A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.
Blood protein patterns may help doctors predict which lymphoma patients will experience severe side effects from CAR-T therapy, enabling preventive care strategies.
This preprint describes a protein biomarker panel in blood that could predict which lymphoma patients will develop severe immune side effects after CAR-T therapy. If validated, this could enable preemptive management of CAR-T toxicities.
What the study was
- Study design
- Biomarker discovery cohort
- Population
- Relapsed/refractory lymphoma patients receiving CAR-T
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- medRxiv
Why it surfaced
Novel biomarker work for CAR-T toxicity prediction in lymphoma. Preprint caps score at 7 max; exploratory design limits further.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.